Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit

SAN FRANCISCO, August 30, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the LD Micro San Francisco Summit taking place September 4th, the CL King 16th Annual Best Ideas Conference and the Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference, both taking place September 13th in New York.

During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio’s first product, key therapeutic programs in development, and upcoming milestones.

Conference Details:
LD Micro San Francisco Summit
Date: Tuesday, September 4, 2018
KindredBio participant: Richard Chin, M.D., President and Chief Executive Officer
Presentation time: 12:30 PM PT
Location: JW Marriott Union Square, SF
CL King 16th Annual Best Ideas Conference
Date: Thursday, September 13, 2018
KindredBio participant: Richard Chin, M.D., President and Chief Executive Officer
Presentation time: 8:00 – 8:35 AM ET
Location: Omni Berkshire Place Hotel, NY, Rockefeller
Webcast URL: Click here
An archived version of the above webcast will be available for 30 days on the Company’s website.
Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference
Date: Thursday, September 13, 2018
KindredBio participant: Katja Buhrer, VP Corporate Development and Investor Relations
Location: Parker New York

Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application.  The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. Please see the full Prescribing Information.

About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio’s first approved drug is Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438